Elevated Capital Advisors LLC Sells 13,424 Shares of Merck & Co., Inc. $MRK

Key Points

• Elevated Capital Advisors LLC cut its Merck stake by 84.6% in the first quarter, selling 13,424 shares and ending with 2,440 shares worth about $293,000.
• Wall Street sentiment remains mixed but generally constructive, with a consensus rating of Moderate Buy and an average price target of $132.72, even as one firm downgraded the stock to Hold.
• Merck gained a key catalyst after the FDA approved KEYTRUDA and KEYTRUDA QLEX with Padcev for use around surgery in muscle-invasive bladder cancer, while investors still weigh long-term patent and valuation risks.

Elevated Capital Advisors LLC lowered its stake in Merck & Co., Inc. (NYSE:MRK - Free Report) by 84.6% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,440 shares of the company's stock after selling 13,424 shares during the quarter. Elevated Capital Advisors LLC's holdings in Merck & Co., Inc. were worth $293,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Kingdom Financial Group LLC. purchased a new stake in shares of Merck & Co., Inc. in the fourth quarter worth about $25,000. Abound Financial LLC bought a new position in Merck & Co., Inc. during the fourth quarter valued at approximately $26,000. Prosperity Bancshares Inc purchased a new position in Merck & Co., Inc. during the 4th quarter valued at approximately $26,000. United Financial Planning Group LLC purchased a new position in Merck & Co., Inc. during the 3rd quarter valued at approximately $31,000. Finally, High Note Wealth LLC increased its stake in Merck & Co., Inc. by 58.9% in the 4th quarter. High Note Wealth LLC now owns 294 shares of the company's stock worth $31,000 after acquiring an additional 109 shares during the last quarter. Institutional investors own 76.07% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on MRK shares. Wall Street Zen cut Merck & Co., Inc. from a "buy" rating to a "hold" rating in a report on Saturday, July 4th. JPMorgan Chase & Co. raised their target price on shares of Merck & Co., Inc. from $125.00 to $135.00 and gave the company an "overweight" rating in a report on Monday, April 6th. Cantor Fitzgerald restated a "neutral" rating and issued a $120.00 price target on shares of Merck & Co., Inc. in a research report on Monday, July 6th. Morgan Stanley boosted their price target on shares of Merck & Co., Inc. from $112.00 to $113.00 and gave the stock an "equal weight" rating in a research report on Thursday. Finally, CICC Research began coverage on shares of Merck & Co., Inc. in a research note on Wednesday, June 24th. They set an "outperform" rating and a $138.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and seven have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $132.72.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: The FDA approved KEYTRUDA and KEYTRUDA QLEX, each combined with Padcev, for use before and after surgery in adults with muscle-invasive bladder cancer. This expands Merck’s flagship oncology franchise and could add to future revenue. Article Title
• Positive Sentiment: Analyst sentiment remains constructive, with Morgan Stanley slightly raising its price target and RBC Capital reiterating a Buy rating. That suggests Wall Street still sees upside despite the stock’s recent run. Article Title
• Positive Sentiment: Merck continues to attract investor attention thanks to strong year-to-date performance, a solid dividend yield, and a long record of dividend growth, which may support demand for the shares. Article Title
• Neutral Sentiment: Recent coverage also notes Merck is one of the more widely watched healthcare names on Zacks, but these mentions do not appear to add any new fundamental catalyst on their own. Article Title
• Negative Sentiment: Despite the upbeat news flow, the shares also face ongoing valuation and post-KEYTRUDA exclusivity concerns, which may limit upside if investors focus on Merck’s long-term patent risk. Article Title

Merck & Co., Inc. Trading Down 1.1%

MRK opened at $123.72 on Friday. The stock has a 50-day moving average of $118.83 and a 200 day moving average of $116.28. The company has a current ratio of 1.30, a quick ratio of 1.06 and a debt-to-equity ratio of 1.02. Merck & Co., Inc. has a 12 month low of $76.66 and a 12 month high of $130.29. The firm has a market cap of $305.56 billion, a P/E ratio of 34.85, a P/E/G ratio of 2.68 and a beta of 0.19.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last issued its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.47) by $0.19. The business had revenue of $16.29 billion for the quarter, compared to the consensus estimate of $15.85 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The company's quarterly revenue was up 4.9% compared to the same quarter last year. During the same period in the prior year, the business posted $2.22 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. As a group, research analysts forecast that Merck & Co., Inc. will post 5.17 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, July 8th. Stockholders of record on Monday, June 15th were given a dividend of $0.85 per share. The ex-dividend date of this dividend was Monday, June 15th. This represents a $3.40 annualized dividend and a dividend yield of 2.7%. Merck & Co., Inc.'s payout ratio is currently 95.77%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.